Literature DB >> 20595473

Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Catherine Bourguinat1, Joseph Kamgno, Michel Boussinesq, Charles D Mackenzie, Roger K Prichard, Timothy G Geary.   

Abstract

Ivermectin (IVM) is exceptionally safe in humans, and is used for mass treatment of onchocerciasis and lymphatic filariasis. However, cases of encephalopathy, sometimes fatal, have been reported in a small number of individuals who harbored large numbers of Loa loa microfilariae (mf). A loss-of-function mutation in the mdr-1 gene in some dog breeds and in mice leads to accumulation of the drug in the brain, causing coma and death. This hypothesis was tested in four individuals from Cameroon who experienced a post-IVM serious adverse event (SAE) and in nine non-SAE matched controls. No loss-of-function mutation was detected in mdr-1 in any subject. However, haplotypes, associated with altered drug disposition, were present as homozygotes in two of the SAE patients (50%), but absent as homozygotes in the controls (0%). An association of high Loa mf load and a genetic predisposition to altered IVM distribution could be involved in IVM SAEs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595473      PMCID: PMC2912571          DOI: 10.4269/ajtmh.2010.09-0734

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  41 in total

1.  Pharmacology of ivermectin.

Authors:  J L Bennett; J F Williams; V Dave
Journal:  Parasitol Today       Date:  1988-08

2.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

3.  Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.

Authors:  Nadine Albermann; Friedrich Hubertus Schmitz-Winnenthal; Kaspar Z'graggen; Christine Volk; Michael Marcus Hoffmann; Walter Emil Haefeli; Johanna Weiss
Journal:  Biochem Pharmacol       Date:  2005-09-15       Impact factor: 5.858

4.  Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain.

Authors:  A T Nies; G Jedlitschky; J König; C Herold-Mende; H H Steiner; H-P Schmitt; D Keppler
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 5.  Therapeutic implications of the MDR-1 gene.

Authors:  K L Mealey
Journal:  J Vet Pharmacol Ther       Date:  2004-10       Impact factor: 1.786

6.  Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors.

Authors:  Gracia Merino; Rebeca Real; Marta F Baro; Lucia Gonzalez-Lobato; Julio G Prieto; Ana I Alvarez; Margarita M Marques
Journal:  Drug Metab Dispos       Date:  2008-09-29       Impact factor: 3.922

Review 7.  Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

Authors:  Zuben E Sauna; Chava Kimchi-Sarfaty; Suresh V Ambudkar; Michael M Gottesman
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 8.  MDR1 gene polymorphisms and clinical relevance.

Authors:  Yan-Hong Li; Yong-Hua Wang; Yan Li; Ling Yang
Journal:  Yi Chuan Xue Bao       Date:  2006-02

9.  Microfilarial distribution of Loa loa in the human host: population dynamics and epidemiological implications.

Authors:  S D S Pion; J A N Filipe; J Kamgno; J Gardon; M-G Basáñez; M Boussinesq
Journal:  Parasitology       Date:  2006-07       Impact factor: 3.234

10.  Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

Authors:  Charles D Mackenzie; Timothy G Geary; John A Gerlach
Journal:  Filaria J       Date:  2003-10-24
View more
  13 in total

1.  Nodding syndrome in Mundri county, South Sudan: environmental, nutritional and infectious factors.

Authors:  P S Spencer; K Vandemaele; M Richer; V S Palmer; S Chungong; M Anker; Y Ayana; M L Opoka; B N Klaucke; A Quarello; J K Tumwine
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

2.  Absence of an association between Plasmodium falciparum infection and post-ivermectin Loa-related non-neurologic serious adverse events.

Authors:  Joël Fokom-Domgue; Sébastien D Pion; Raceline Gounoue; Julie Akame; Patrick Nguipdop-Djomo; Nana A Y Twum-Danso; Björn Thylefors; Michel Boussinesq; Joseph Kamgno
Journal:  Am J Trop Med Hyg       Date:  2014-01-13       Impact factor: 2.345

Review 3.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

Review 4.  P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.

Authors:  Anne Lespine; Cécile Ménez; Catherine Bourguinat; Roger K Prichard
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2011-11-07       Impact factor: 4.077

Review 5.  A research agenda for helminth diseases of humans: intervention for control and elimination.

Authors:  Roger K Prichard; María-Gloria Basáñez; Boakye A Boatin; James S McCarthy; Héctor H García; Guo-Jing Yang; Banchob Sripa; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

6.  Prospects for Moxidectin as a New Oral Treatment for Human Scabies.

Authors:  Kate E Mounsey; Charlotte Bernigaud; Olivier Chosidow; James S McCarthy
Journal:  PLoS Negl Trop Dis       Date:  2016-03-17

7.  In vitro and in vivo evaluation of 2-aminoalkanol and 1,2-alkanediamine derivatives against Strongyloides venezuelensis.

Authors:  Ana L Legarda-Ceballos; Julio López-Abán; Esther Del Olmo; Ricardo Escarcena; Luis A Bustos; Jose Rojas-Caraballo; Belén Vicente; Pedro Fernández-Soto; Arturo San Feliciano; Antonio Muro
Journal:  Parasit Vectors       Date:  2016-06-28       Impact factor: 3.876

8.  Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae.

Authors:  Carlos J Chaccour; Felix Hammann; Marta Alustiza; Sandra Castejon; Brian B Tarimo; Gloria Abizanda; Ángel Irigoyen Barrio; Helena Martí Soler; Rafael Moncada; José Ignacio Bilbao; Azucena Aldaz; Marta Maia; José Luis Del Pozo
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

9.  Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.

Authors:  Cécile Ménez; Jean-François Sutra; Roger Prichard; Anne Lespine
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?

Authors:  Rebecca E Chandler
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.